Overview

Safety and Efficacy of Sofosbuvir/Velpatasvir/Voxilaprevir in Adults With Chronic HCV Infection Who Have Previously Received Treatment With Direct-Acting Antiviral Therapy

Status:
Completed

Trial end date:
2017-06-21

Target enrollment:

Participant gender:

Summary

The primary objectives of this study are to evaluate the safety and efficacy of treatment with sofosbuvir/velpatasvir/voxilaprevir (SOF/VEL/VOX) in adults with chronic hepatitis C virus (HCV) infection who have previously received treatment with direct-acting antiviral therapy. Participants randomized to placebo may be eligible for deferred treatment with active SOF/VEL/VOX.

Phase:

Phase 3

Details

Lead Sponsor:

Gilead Sciences

Treatments:

Antiviral Agents
Sofosbuvir
Velpatasvir